Neo-adjuvant Chemotherapy Evluation in Gastric Cancer Patients Based on Circulating Exosomal LncRNA-GC1
- Conditions
- Gastric CancerChemotherapy Effect
- Registration Number
- NCT05647941
- Lead Sponsor
- Chinese PLA General Hospital
- Brief Summary
The investigators hope that through the analysis and research to find determine whether lncRNA-GC1 could serve as a non-invasive biomarker for monitoring the neo-adjuvant chemotherapy response for personalized medicine for gastric cancer.
- Detailed Description
The LncRNA-GC1could noninvasively track dynamics of tumor burden and has been proposed as a real-time biomarker that can provide both predictive and prognostic values. But the value in monitoring the neo-adjuvant chemotherapy response is unclear. The investigators hope that through the analysis and research to find determine whether lncRNA-GC1 could serve as a monitoring biomarker for patients with gastric cancer receiving neo-adjuvant chemotherapy.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 700
- Having signed informed consent
- Age≥ 18 years old
- Histologically confirmed gastric adenocarcinoma
- radiographically identified as advanced gastric cancer
- Other previous malignancy within 5 year
- Surgery (excluding diagnostic biopsy) within 4 weeks prior to study
- Pregnancy or lactation period
- Legal incapacity
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Detection of levels of circulating exosomal lncRNA-GC1 Through study completion, an average of 1 year Levels of circulating exosomal lncRNA-GC1 are detected by RT-PCR
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Chinese PLA General Hospital Ethics Committee
🇨🇳Beijing, Beijing, China